SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gland Pharma - Quaterly Results

05 Aug 2025 Evaluate
The total revenue for the quarter ended June 2025 remained nearly unchanged at Rs. 10388.35 millions.The Company has registered profit of Rs. 2692.58  millions for the quarter ended June 2025, a growth of 20.79%  over Rs. 2229.21 millions millions achieved in the corresponding quarter of last year.Operating profit for the quarter ended June 2025 rose to 4135.86 millions as compared to 3420.43 millions of corresponding quarter ended June 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 10388.35 10120.24 2.65 10388.35 10120.24 2.65 41161.49 41674.28 -1.23
Other Income 547.41 484.90 12.89 547.41 484.90 12.89 2150.75 1666.66 29.05
PBIDT 4135.86 3420.43 20.92 4135.86 3420.43 20.92 16576.93 15754.47 5.22
Interest 74.35 9.11 716.14 74.35 9.11 716.14 228.37 78.43 191.18
PBDT 4061.51 3411.32 19.06 4061.51 3411.32 19.06 16348.56 15676.04 4.29
Depreciation 437.68 408.17 7.23 437.68 408.17 7.23 1692.71 1621.07 4.42
PBT 3623.83 3003.15 20.67 3623.83 3003.15 20.67 14655.85 14054.97 4.28
TAX 931.25 773.94 20.33 931.25 773.94 20.33 3758.32 3621.72 3.77
Deferred Tax -1.46 11.82 -112.35 -1.46 11.82 -112.35 91.24 246.84 -63.04
PAT 2692.58 2229.21 20.79 2692.58 2229.21 20.79 10897.53 10433.25 4.45
Equity 164.76 164.75 0.01 164.76 164.75 0.01 164.76 164.71 0.03
PBIDTM(%) 39.81 33.80 17.80 39.81 33.80 17.80 40.27 37.80 6.53

Gland Pharma Share Price

1756.00 34.30 (1.99%)
15-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.65
Dr. Reddys Lab 1218.30
Cipla 1226.65
Zydus Lifesciences 936.00
Lupin 2339.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×